Bloomage Biotechnology Corp Ltd - Asset Resilience Ratio
Bloomage Biotechnology Corp Ltd (688363) has an Asset Resilience Ratio of 0.35% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Bloomage Biotechnology Corp Ltd balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2024)
This chart shows how Bloomage Biotechnology Corp Ltd's Asset Resilience Ratio has changed over time. See net assets of Bloomage Biotechnology Corp Ltd for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Bloomage Biotechnology Corp Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Bloomage Biotechnology Corp Ltd stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥30.02 Million | 0.35% |
| Total Liquid Assets | CN¥30.02 Million | 0.35% |
Asset Resilience Insights
- Limited Liquidity: Bloomage Biotechnology Corp Ltd maintains only 0.35% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Bloomage Biotechnology Corp Ltd Industry Peers by Asset Resilience Ratio
Compare Bloomage Biotechnology Corp Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Akzo Nobel NV
AS:AKZA |
Specialty Chemicals | 2.16% |
|
Luxi Chemical Group Co Ltd
SHE:000830 |
Specialty Chemicals | 0.43% |
|
Dyno Nobel Ltd
AU:DNL |
Specialty Chemicals | 13.89% |
|
Lianhe Chemical Technology Co Ltd
SHE:002250 |
Specialty Chemicals | 0.44% |
|
Sichuan Tianqi Lithium Industries Inc
SHE:002466 |
Specialty Chemicals | 2.06% |
|
Jiangsu Yida Chemical Co Ltd Class A
SHE:300721 |
Specialty Chemicals | 4.73% |
|
Asia Cuanon Tech (Shanghai)
SHG:603378 |
Specialty Chemicals | 0.02% |
|
Xiamen Yanjan New Material Co Ltd
SHE:300658 |
Specialty Chemicals | 1.45% |
Annual Asset Resilience Ratio for Bloomage Biotechnology Corp Ltd (2012–2024)
The table below shows the annual Asset Resilience Ratio data for Bloomage Biotechnology Corp Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.35% | CN¥30.02 Million ≈ $4.39 Million |
CN¥8.66 Billion ≈ $1.27 Billion |
-1.31pp |
| 2023-12-31 | 1.65% | CN¥140.04 Million ≈ $20.49 Million |
CN¥8.47 Billion ≈ $1.24 Billion |
-4.46pp |
| 2022-12-31 | 6.11% | CN¥530.72 Million ≈ $77.66 Million |
CN¥8.68 Billion ≈ $1.27 Billion |
-5.17pp |
| 2021-12-31 | 11.29% | CN¥846.89 Million ≈ $123.93 Million |
CN¥7.50 Billion ≈ $1.10 Billion |
-1.36pp |
| 2020-12-31 | 12.64% | CN¥722.70 Million ≈ $105.75 Million |
CN¥5.72 Billion ≈ $836.56 Million |
-3.46pp |
| 2019-12-31 | 16.11% | CN¥800.70 Million ≈ $117.17 Million |
CN¥4.97 Billion ≈ $727.51 Million |
+3.87pp |
| 2017-12-31 | 12.23% | CN¥230.38 Million ≈ $33.71 Million |
CN¥1.88 Billion ≈ $275.55 Million |
+3.95pp |
| 2014-12-31 | 8.29% | CN¥80.00 Million ≈ $11.71 Million |
CN¥965.44 Million ≈ $141.27 Million |
-4.34pp |
| 2013-12-31 | 12.63% | CN¥97.00 Million ≈ $14.19 Million |
CN¥768.31 Million ≈ $112.43 Million |
+3.14pp |
| 2012-12-31 | 9.49% | CN¥45.00 Million ≈ $6.58 Million |
CN¥474.26 Million ≈ $69.40 Million |
-- |
About Bloomage Biotechnology Corp Ltd
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature nam… Read more